STOCK TITAN
  1. Home
  2. News
  3. TNXP

Tonix Pharmaceuticals Holding Corp - TNXP STOCK NEWS

Welcome to our dedicated news page for Tonix Pharmaceuticals Holding (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceuticals Holding.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tonix Pharmaceuticals Holding's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tonix Pharmaceuticals Holding's position in the market.

News
Tonix Pharmaceuticals Selects EVERSANA® to Support Launch Strategy and Commercialization Planning of Tonmya™ for the Management of Fibromyalgia
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces EVERSANA as partner for the launch strategy of Tonmya, a potential first-line non-opioid analgesic for fibromyalgia. Positive Phase 3 trial results support NDA submission to FDA in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
none
-
News
Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces promising results for TNX-1500, a third-generation anti-CD40L mAb with reduced thrombosis risk and potential peak sales exceeding €5B per year. TNX-1500 shows positive PK properties in animal studies, supporting monthly dosing, and has multiple potential indications in transplantation and autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.25%
Tags
none
-
News
Tonix Pharmaceuticals Announces Presentation at The 6th International Congress on Controversies in Fibromyalgia
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces presentation of additional data from positive Phase 3 RESILIENT trial of Tonmya™ for fibromyalgia management at The 6th International Congress on Controversies in Fibromyalgia. The company focuses on CNS disorders and plans to submit an NDA to the FDA in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
none
News
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. completes Phase 1 trial of TNX-1500, a potential treatment for organ transplant rejection and autoimmune disorders. Positive clinical data from Sanofi's frexalimab in multiple sclerosis. Topline results expected in Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Tonix Pharmaceuticals Announces Positive Results from Clinical Pharmacokinetic Bridging Study of Tonmya™ to Support Development and Partnering in Japan and China
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces positive results from a clinical pharmacokinetic bridging study of Tonmya in ethnic Japanese and Chinese volunteers. The study supports plans to file a Clinical Trial Notification in Japan and an Investigational New Drug application in China for a registration-enabling Asian Phase 3 study. Tonmya's market exclusivity is backed by patents in Japan, China, Hong Kong, and Taiwan. The New Drug Application submission to the U.S. FDA for Tonmya's approval for fibromyalgia management is scheduled for the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.82%
Tags
none
-
News
New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain
Rhea-AI Summary
Tonix Pharmaceuticals (TNXP) has developed a bedtime drug targeting fibromyalgia's poor sleep quality, showing promising results in reducing widespread pain. The drug, Tonmya, demonstrated significant pain improvement in a phase 3 study, with a potential FDA approval in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
none
News
Tonix Pharmaceuticals to Participate in the 2024 BIO CEO & Investor Conference
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces CEO's participation at BIO CEO & Investor Conference to discuss the company's pipeline of development candidates, including positive Phase 3 studies for fibromyalgia treatment and plans for NDA submissions. The company's focus on CNS disorders and rare diseases, breakthrough therapy designation for TNX-1300, and vaccine development for smallpox and COVID-19 are highlighted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
conferences
-
News
Tonix Drug Shown To Relieve Pain in Fibromyalgia Without Risk of Addiction
Rhea-AI Summary
Tonix Pharmaceuticals (NASDAQ: TNXP) reported positive Phase 3 trial results for its non-opioid painkiller for fibromyalgia, achieving the primary endpoint with a p-value of 0.00005. The drug, Tonmya, showed promising results in reducing pain, improving sleep, and reducing fatigue. With potential FDA approval in 2025, Tonmya could offer a new treatment option for fibromyalgia patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya™, Plans to File NDA for FDA Approval in Second Half of 2024
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces positive Phase 3 data for Tonmya™ (TNX-102 SL) for fibromyalgia management, showcasing significant reduction in pain, fatigue, and sleep disturbance. Plans to file for FDA approval in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.43%
Tags
clinical trial fda approval
News
Tonix Pharmaceuticals Announces Engagement of Rho as CRO to Support Submission of New Drug Application to the FDA for Approval of Tonmya™ for the Management of Fibromyalgia
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. engages Rho, Inc. for NDA submission of Tonmya™, a potential first-line therapy for fibromyalgia. Positive Phase 3 results show significant pain reduction compared to placebo, with plans for NDA submission in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
none
Stock TNXP logo
Tonix Pharmaceuticals Holding Corp

Nasdaq:TNXP

TNXP Rankings

#5248 Ranked by Market Cap
#5322 Ranked by Stock Gains
N/A Ranked by Dividends

TNXP Stock Data

15.53M
84.49M
0.01%
19.85%
1.7%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Chatham

About TNXP

tonix is developing innovative pharmaceutical products to address major public health challenges. in addition to tonmya for ptsd, tonix is developing tnx-601 (tianeptine oxalate), a clinical candidate at pre-ind (investigational new drug) application stage, designed as a daytime treatment for ptsd and tnx-801, a live synthetic version of horsepox virus, at the pre-ind application stage, to be developed as a potential smallpox-preventing vaccine. further information about tonix can be found at www.tonixpharma.com.